Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Nexavar Sorafenib tablets Cancer, Renal cell carcinoma Do not list Complete
Nexavar Sorafenib Metastatic Progressive Differentiated Thyroid Carcinoma (DTC) Do not reimburse Complete
Nexplanon etonogestrel Prevention of pregnancy Reimburse with clinical criteria and/or conditions Complete
Nexviazyme avalglucosidase alfa Pompe disease Reimburse with clinical criteria and/or conditions Complete
Ngenla somatrogon Growth hormone deficiency Reimburse with clinical criteria and/or conditions Complete
Ninlaro Ixazomib Multiple Myeloma (2nd-beyond) Do not reimburse Complete
Ninlaro Ixazomib Multiple Myeloma Do not reimburse Complete
Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete
Norprolac Quinagolide hydrochloride Hyperprolactinemia Do not list Complete
Norprolac Quinagolide hydrochloride Hyperprolactinemia List with clinical criteria and/or conditions Complete
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete
Nplate Romiplostim Chronic immune (idiopathic) thrombocytopenic purpura (ITP) Do not list Complete
Nubeqa Darolutamide non-metastatic castration resistant prostate cancer (nmCRPC) Reimburse with clinical criteria and/or conditions Complete
Nubeqa darolutamide Metastatic castration-sensitive prostate cancer Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Severe chronic rhinosinusitis with nasal polyps Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Eosinophilic granulomatosis with polyangiitis Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Nucala mepolizumab Asthma, severe eosinophilic (pediatric) Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Nucala Mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete
Nucynta tapentadol hydrochloride pain, severe Do not reimburse Complete
Nucynta CR Tapentadol Pain, moderate to moderately severe Do not list Complete
Nurtec ODT rimegepant Migraine, prevention Withdrawn
NuvaRing Etonogestrel/ethinyl estradiol Contraceptive, ring List with clinical criteria and/or conditions Complete
Ocaliva Obeticholic Acid Primary Biliary Cholangitis Reimburse with clinical criteria and/or conditions Complete
Ocrevus ocrelizumab multiple sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete